Skip to main content

06.22.23

ShareTreck: Jeff Galvin Weighs in on Addimmune’s Launch and AGT103-T Updates

Addimmune™ CEO Jeff Galvin joins ShareTreck host Raj Natarajan in this compelling interview to discuss the company’s launch as well as updates on AGT103-T, Addimmune’s HIV therapeutic. Following a successful Phase 1 clinical trial, will build AGT’s success, accelerating the clinical development with dedicated investment and singular focus on HIV. 

Watch Video Here

1rem 0 1 all hidden top 87.5% 0 1 .001 1.5 expo.out .1 .pinme false top 71 bottom bottom top center bottom bottom true 0 1 top center bottom bottom true 0 1 .navbar-inner false top top 99999px 0 none top -100 top -200 true play none none reverse 1 0 1px 3px 0 rgb(0 0 0 / 0.1), 0 1px 2px -1px rgb(0 0 0 / 0.1) none 1 true top 90% 0 2 .25 .001 power4.out